ClinicalTrials.gg
RecruitingNCT06792643SURVIVEUpdated Jan 27, 2025

Cangrelor on Top of AnticoagUlation in Patients with MyocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest ReceiVIng VA-ECMO

A Phase 2 interventional study of Cangrelor in Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication and Platelet Dysfunction, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-27.

Sponsored by IRCCS San Raffaele · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Shock, Cardiogenic with a site in Italy — 10 open to participants now, 12 under way, none of them phase 3. Shock, Cardiogenic · Italy.

Started
2024
with 5 others
Phase 2
3 of 20
1 open now
Primary completion
2025-10
later than 4 of 11 live
Registered
13th of 20
by date

Among the 20 studies in Shock, Cardiogenic with a site in Italy, this one is one of 6 that started in 2024, is one of 3 in phase 2, reaches primary completion later than 4 of the 11 other live ones, and was the 13th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

10 of the 20 studies in Shock, Cardiogenic with a site in Italy are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Shock, Cardiogenic with a site in Italy, or all of them as a file.
02

Study summary

The SURVIVE trial aims to test whether using an anti-thrombotic regimen involving cangrelor can reduce bleeding risk while maintaining effective antithrombotic effects in patients on VA-ECMO due to cardiogenic shock (CS)/ cardiac arrest (CA) who undergo percutaneous coronary intervention (PCI). The investigators plan to achieve this by starting cangrelor on top of systemic anticoagulation with bivalirudin at a low dose, regularly monitoring platelet function, and adjusting the dose based on the results of platelet function assay (Multiplate®) to guarantee effective platelet P2Y12 pathway inhibition to achieve optimal platelet inhibition. Platelet function assays will be performed at various time points throughout the treatment timeframe. Cangrelor will then be stopped at the end of VA-ECMO support, and patients will be transitioned to oral P2Y12- inhibitors as per clinical guidelines.

Read the detailed description

Veno-Arterial Extra Corporeal Membrane Oxygenation (VA-ECMO) is increasingly used to support patients throughout a spectrum of hemodynamic instability states ranging from severe cardiogenic shock (CS) to refractory cardiac arrest (CA). VA-ECMO, is thus often employed in clinical practice for the management of CS/CA complicating acute coronary syndromes (ACS). The interface of blood and VA-ECMO mechanical components, along with rotational forces generated by pump impellers configures a unique combination of prothrombotic and pro-haemorrhagic milieu (haemocompatibility). In this setting of competing thrombotic and hemorrhagic risks, optimal anti-thrombotic therapy remains ill-defined for patients undergoing percutaneous coronary intervention (PCI) for ACS on VA-ECMO. Theoretically, dual anti-platelet therapy (DAPT) consisting of aspirin plus an oral P2Y12 inhibitor should be associated with systemic anticoagulation (triple antithrombotic therapy). Platelet activation during ECMO support confers increased thrombotic risk, which, in the setting of ACS-related CS/CA, is worsened by the pro-thrombotic and pro-inflammatory state, the low-cardiac output with subsequent blood stasis and tissue hypoperfusion and possibly the need for myocardial revascularization procedure with stent implantation. At the same time, blood interaction with device foreign surfaces has been associated to reduced platelet surface expression of GpIb-GpIV, lower activated surface GpIIb-IIIa levels and blunted ADP-mediated aggregation, which translate into increased bleeding risk. Bleeding complications, however, exceed ischemic risk and triple antithrombotic therapy may confer an excess risk in this population prone to bleeding and may jeopardize patients' outcome. In this context of delicate haemostatic equilibrium several pharmacokinetic and pharmacodynamic factors limit the use of standard DAPT in addition to systemic anticoagulation, including the irreversible inhibiting effect of aspirin on platelets and the relatively long duration of action of oral P2Y12 inhibitors.

In addition, while GpIIb-IIIa inhibitors may offer a parenteral alternative antiplatelet agent, their use has been associated with increased transfusion need during VA-ECMO. The study hypothesis is that an anti-thrombotic regimen comprising cangrelor, an intravenous non-thienopyridine, reversible adenosine-diphosphate P2Y12 receptor antagonist, may reduce bleeding risk while providing adequate antithrombotic effect in patients on VA ECMO due to CS/CA who underwent PCI. Both the rapid onset and offset of action of this agent make it a particularly attractive option in patients at a high risk of both thrombotic and haemorrhagic complications, since a combination of a low starting dose of cangrelor coupled with regular platelet function tests potentially guarantees achieving adequate anti-platelet effect at the lowest possible cangrelor dose, in order to prevent ischemic events while minimizing bleeding risk.

Systemic anticoagulation will be performed with bivalirudin, titrated to achieve effective systemic anticoagulation and an activated thromboplastin time (aPTT) of 55-70'', as for routine clinical practice. Cangrelor will be started without bolus at a low dose of 0.125 mcg/kg/min and titrated (by 0.125 mcg/kg/min steps) based on the results of platelet function assay to guarantee effective platelet P2Y12 pathway inhibition. Platelet function will be assessed with the Multiplate analyser with the aim to reach and ADP-test \<46 U. Platelet assay will be performed at baseline, 30 min after cangrelor infusion start, 12 hours after cangrelor infusion start, after any cangrelor dose modulation, regularly every 24 hours, at time of any thrombotic/bleeding event, and up to 48 hours from oral P2Y12-inhibitor initiation. Treatment with cangrelor will be discontinued at the end of VA-ECMO support, and patients will be loaded with oral P2Y12-inhibitors, as recommended for clinical practice.

03

Conditions studied

  • Cardiogenic Shock
  • Extracorporeal Membrane Oxygenation Complication
  • Platelet Dysfunction

Keywords

  • Cangrelor
  • ACS
  • Cardiogenic Shock
  • PCI
  • ECMO
  • VA-EMO
  • Acute coronary syndrome
  • P2Y12
  • Anti-thrombotic therapy
  • Extracorporeal Membrane Oxygenation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged ≥18 years;
  • ACS-related CS/CA patients undergoing PCI (either with or without stent implantation) and needing VA-ECMO support;
  • Patients who received pre-hospital aspirin intravenous loading dose or patients naïve to any anti-thrombotic agent;
  • Written

Exclusion criteria

Exclusion Criteria:

  • Overt uncontrollable bleeding;
  • Suspected intra-cranial haemorrhage;
  • Patients who received any dose of any oral P2Y12-inhibitors;
  • Patients with known history of stroke or (TIA);
  • Patients with known to the active substance (cangrelor) or to any of its ;
  • Pregnancy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Cangrelor

    Cangrelor will be started without bolus at a low dose of 0.125 mcg/kg/min and titrated (by 0.125 mcg/kg/min steps) based on the results of platelet function assay to guarantee effective platelet P2Y12 pathway inhibition.

    Drug: Cangrelor

Interventions

  • Cangrelor will be started without bolus at a low dose of 0.125 mcg/kg/min and titrated (by 0.125 mcg/kg/min steps) based on the results of platelet function assay to guarantee effective platelet P2Y12 pathway inhibition.

06

What researchers measure

Primary outcomes

  1. Major bleeding [type 3b or 5 Bleeding Academic Research Consortium (BARC) bleeding] - Safety outcome

    Major bleeding will be defined as type 3b or 5 Bleeding Academic Research Consortium (BARC) bleeding.

    Time frame: Up to 48 hours after ECMO support withdrawal

  2. Thrombotic events - Efficacy outcome

    Thrombotic events will be defined as: any new myocardial infarction, any definite or probable stent thrombosis (ST) according to Academic Research Consortium (ARC)-2 criteria, any peripheral arterial thrombosis, any venous thrombosis/venous thromboembolism or imaging-defined ischemic stroke.

    Time frame: Up to 48 hours after ECMO support withdrawal

  3. Multiplate assay with ADP-test values <46 U

    Multiplate assay with ADP-test values \<46 U (time in therapeutic range)

    Time frame: Up to 48 hours after ECMO support withdrawal

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data will be available upon reasonable request after approval of the PI.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Oct 2025, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2023
First posted
Jan 27, 2025
StartActual
Apr 1, 2024
Primary completionEst.
Oct 29, 2025
CompletionEst.
Dec 31, 2025
Last update
Jan 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06792643
Lead sponsor
IRCCS San Raffaele
Responsible party
Anna Mara Scandroglio (Principal Investigator, IRCCS San Raffaele) — Principal investigator
First posted
Jan 27, 2025
Start date
Apr 1, 2024
Primary completion
Oct 29, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jan 27, 2025

Study contacts

Marina Pieri, MD
Contact
pieri.marina@hsr.it
0039 0226437722
Luca Baldetti, MD
Contact
baldetti.luca@hsr.it
0039 0226437722

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cangrelor

Start the discussion